An ASGCT preview; plus the latest in accelerated approval and Biosecure — a BioCentury podcast

An explosion of CAR T applications among key themes at this year’s ASGCT meeting 

One of the big themes of this week’s ASGCT meeting will be CAR T cells in cancer and beyond. On the latest BioCentury This Week podcast, BioCentury’s editors preview the American Society of Gene and Cell Therapy’s annual meeting.

Much of the CAR T field has reoriented from cancer to autoimmune diseases over the past year. Now, researchers are looking even farther afield. According to abstracts released ahead of ASGCT, the engineered T cell modality may have new benefits to offer patients with asthma, Duchenne muscular dystrophy or HIV. 

Other themes at the meeting that BioCentury will be covering include progress in epigenetic editors, vectorized antibody therapies, and methods to target AAVs to the central nervous system.

On this week’s podcast, BioCentury’s editors also discuss a study aiming to quantify the benefits accelerated approval has had for cancer patients, and what’s next for the Biosecure Act and similar legislation seeking to rein in Chinese CDMOs and genomics companies.

The BioCentury Show, featuring senior editors one-on-one with an industry KOL, is now available as a podcast. It’s also available via BioCentury’s YouTube channel.